Integrin Alpha 4 (ITGA4/CD49d) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 19 Sep 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Therapeutic Development.

TarMart Solution Ecosystem & Related Targets

"Comprehensive reagent toolkit for ITGA4 drug discovery. Select your modality below:"

Component / Network Product Description Product Link
Antigen ITGA4/ITGB1 Heterodimer & ITGA4/ITGB7 Heterodimer Proteins
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation).		 View ITGA4 Products
Gene Delivery ITGA4 Lentivirus Premade Particles
Full-length ORF for stable cell line construction and cell-based adhesion assays.		 View ITGA4 Products
Benchmark Ab Anti-ITGA4 Recombinant Antibody (Natalizumab Biosimilar)
Recombinant positive control for binding and blocking assays.		 View ITGA4 Products
Validator ITGA4 siRNA Set
For knockdown verification in target specificity validation.		 View ITGA4 Products
Related Target A ITGB1 (Integrin Beta 1)
Pairs with ITGA4 to form VLA-4 (alpha4beta1), key for CNS leukocyte migration.		 View ITGB1 Products
Related Target B ITGB7 (Integrin Beta 7)
Pairs with ITGA4 to form LPAM-1 (alpha4beta7), gut-homing cell adhesion receptor.		 View ITGB7 Products
Related Target C MADCAM1
Specific endothelial ligand for alpha4beta7 integrin, critical for IBD therapeutics.		 View MADCAM1 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Conformation-dependent heterodimer stability HEK293 co-expressed ITGA4/ITGB1 and ITGA4/ITGB7 heterodimers with native folding and glycosylation profiles.
Selectivity screening (VLA-4 vs. alpha4beta7) Both ITGA4/ITGB1 and ITGA4/ITGB7 recombinant proteins and lentivirus-driven cell lines are available for side-by-side profiling.
Lack of Controls Clinical Benchmark Antibodies (Natalizumab and Vedolizumab biosimilars) included as positive controls.
False Positives Validated siRNA included for specificity and functional knockdown verification.

Live ITGA4 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for ITGA4 therapeutics is intensifying, with major players shifting focus from systemic integrin blockade to organ-selective inhibition. As first-generation therapies like Natalizumab (which targets both alpha4beta1 and alpha4beta7) reach mature clinical use, next-wave R&D is targeting selective gut-homing pathways (alpha4beta7) and oral small-molecule inhibitors to bypass the progressive multifocal leukoencephalopathy (PML) risks associated with systemic immune suppression.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Monoclonal Antibodies Biogen, Takeda, Roche Multiple Sclerosis, Inflammatory Bowel Disease (IBD) Selectivity Assay (Need high-purity ITGA4/ITGB1 vs ITGA4/ITGB7 heterodimers)
Small Molecules EA Pharma, Morphic Therapeutic Ulcerative Colitis, Crohn's Disease Cell-based Adhesion Assay (Need Lentivirus for Stable Cell Line development)
Bispecific Antibodies Academic / Biotech Refractory Autoimmune, Colorectal Cancer Target Engagement Validation (Need recombinant MADCAM1 and VCAM1 ligands)